![\"\"](\"https:\/\/www.newsbeep.com\/us-tx\/wp-content\/uploads\/2025\/10\/OvertureLife_HansGangeskar-970.jpg\")
<\/p>\n <\/p>\n
Hans Gangeskar, CEO of Overture Life [Composite image; Original photo: Hans Gangeskar\/LinkedIn]<\/p>\n
Palo Alto, California-based Overture Life\u2014the company behind \u201cthe world\u2019s first babies born from robotic fertilization and robotic egg freezing\u201d\u2014has opened its U.S. clinical operations headquarters in Dallas\u00a0 The site will run non-invasive, CLIA-licensed embryo-assessment testing that analyzes molecules in the fluid surrounding embryos, with machine-learning support. Overture says this will give fertility teams \u201cobjective data to inform embryo selection without a biopsy.\u201d<\/p>\n
The company\u2019s first dedicated U.S. laboratory, the facility in the Bogart Building at 4621 Ross Avenue will help the company accelerate deployment of its automated IVF platforms, which currently operate in clinics across Brazil, Argentina, Chile, Bolivia, Panama, Turkey, and New Jersey.<\/p>\n
Overture was originally founded in Madrid, Spain, in 2017.<\/p>\n
\u201cThis Dallas hub bridges our European manufacturing and research operations with North American markets,\u201d CEO Hans Gangeskar said in a statement.\u00a0\u201cThe central U.S. location facilitates national logistics while giving us access to the biomedical engineering and data science talent concentrated in Texas.\u201d<\/p>\n
Freezing eggs with \u2018robotic precision\u2019
\n![\"\"](\"https:\/\/www.newsbeep.com\/us-tx\/wp-content\/uploads\/2025\/10\/Hafsa-Irfan-head-of-clinical-operations-in-Dallas-for-Overture-Life-Photo-Overture-copy.jpg\")
<\/p>\n
Hafsa Irfan<\/p>\n
The company said its new Dallas facility will anchor its U.S. expansion as demand builds for its DaVitri automated egg-freezing system. The platform freezes eggs with robotic precision, Overture said, achieving a 12% improvement in egg survival rates \u201cwhile allowing clinics to process three times the number of procedures without adding staff.\u201d<\/p>\n
Hafsa Irfan is head of clinical operations for the Dallas facility and will be overseeing\u00a0 the lab\u2019s scientific build-out and operations and metabolomics assay optimization.<\/p>\n
\u201cThe infrastructure we\u2019re establishing here, from our non-invasive embryo assessment technology to quality systems, creates the foundation for scaling automated fertility care across the United States,\u201d Irfan said in a statement.<\/p>\n
Dallas facility a \u2018multi-million-dollar\u2019 investment<\/p>\n
Overture said the lab equipment and infrastructure at its new Dallas facility represent \u201ca multi-million-dollar investment\u201d in advanced technical capabilities.<\/p>\n
The facility will focus on non-invasive embryo testing that provides fertility teams with molecular data to guide treatment decisions\u2014without requiring embryo biopsies. The facility\u2019s design accommodates expanded lab services and continued advancement of AI-driven automation protocols, the company said, including building \u201ca continuously learning, regulated automation layer,\u201d which is the infrastructure that makes AI-driven IVF reproducible, measurable, and clinically validated.<\/p>\n
Selecting Dallas for its \u2018growing biomedical workforce\u2019 and more<\/p>\n
The company said Dallas emerged as the location choice due to its concentration of life sciences companies, proximity to research institutions including UT Southwestern Medical Center, and growing biomedical workforce. It noted that North Texas\u2019 biomedical sector employs over 27,000 professionals across 850 companies\u2014with particular strength in medical device development and clinical research.<\/p>\n
Overture said it will be hiring for positions across product development, clinical operations, laboratory operations, manufacturing, quality assurance, regulatory affairs, and commercial functions at its Dallas facility. In addition, the Dallas lab will coordinate with Overture\u2019s R&D operations in Spain and the company\u2019s growing network of clinical partners.<\/p>\n
The Dallas lab is joining Overture\u2019s facilities in Spain amid the company\u2019s buildout of infrastructure to meet growing demand. Overture says its DaVitri system\u2019s European pre-order waitlist, launched in September, \u201cfilled within weeks\u201d as clinics sought automation systems with \u201cdocumented healthy births\u201d and peer-reviewed clinical outcomes.<\/p>\n
Platform standardizes the egg freezing process<\/p>\n
Overture said its automation portfolio addresses the most technically demanding procedures in IVF. In 2024, the company\u2019s ICSI.A system \u201cachieved the world\u2019s first babies born from robotic sperm injection,\u201d Overture said. Its DaVitri platform \u201cstandardizes\u201d the egg freezing process, which typically requires years of specialized training.<\/p>\n
Together, these systems help laboratories deliver consistent results, Overture said, while reducing the physical strain on embryologists who perform thousands of precise manual procedures annually.<\/p>\n
Don\u2019t miss what\u2019s next. Subscribe\u00a0to\u00a0Dallas\u00a0Innovates.<\/p>\n
Track Dallas-Fort Worth\u2019s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.<\/p>\n
\u00a0<\/p>\n
\tR E A D\u00a0\u00a0 N E X T\t<\/p>\n
\t The southern half of Dallas County is home to just over 1.05 million residents. That\u2019s about 40% of the total number of people who call Dallas County home\u2014and roughly 200,000 more than the entire population of San Francisco. Coupled with the fact that Dallas-Fort Worth is emerging as a top life science market, as documented in a 2023 CBRE report, you can see why the DeSoto Development Corp. is including an 80-acre Life Sciences Innovation Core among its major projects. \u201cIn terms of economic development, research shows that it\u2019s more effective when it happens regionally,\u201d says Matt Carlson, DDC’s chief\u2026<\/p>\n \t The North Texas-based precision oncology firm raised $494 million in its IPO. Founder David Halbert is now a newly minted biotech billionaire worth an estimated $3.3 billion, Forbes reports.<\/p>\n \t At its Dallas Design District grand opening, Koya Medical marked the official move of its headquarters from California\u2014bringing with it a wearable alternative to wall-powered compression therapy for vascular patients. \u201cThis is something that is different from anything that is out there,\u201d says vascular surgeon and new CMO Tom Maldonado.<\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/us-tx\/wp-content\/uploads\/2025\/10\/LifeScience_DeSoto-parcels-970.jpg\")
<\/a><\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/us-tx\/wp-content\/uploads\/2025\/10\/CarisLifeSciences_970-courtesy-970x464.jpg\")
<\/a><\/p>\n![\"\"](\"https:\/\/www.newsbeep.com\/us-tx\/wp-content\/uploads\/2025\/10\/Koya-Opneing-2up-NW-970.jpg\")
<\/a><\/p>\n
![\"Merritt](\"https:\/\/www.newsbeep.com\/us-tx\/wp-content\/uploads\/2025\/10\/Merritt-Westcott-high-res_970.jpg\")
<\/a><\/p>\n